MX2018002033A - Agentes antibacterianos que comprenden una pirazino[2,3-b] [1,4]oxazin-3-ona o un sistema de anillo relacionado. - Google Patents

Agentes antibacterianos que comprenden una pirazino[2,3-b] [1,4]oxazin-3-ona o un sistema de anillo relacionado.

Info

Publication number
MX2018002033A
MX2018002033A MX2018002033A MX2018002033A MX2018002033A MX 2018002033 A MX2018002033 A MX 2018002033A MX 2018002033 A MX2018002033 A MX 2018002033A MX 2018002033 A MX2018002033 A MX 2018002033A MX 2018002033 A MX2018002033 A MX 2018002033A
Authority
MX
Mexico
Prior art keywords
pyrazino
oxazin
ring system
antibacterial agents
related ring
Prior art date
Application number
MX2018002033A
Other languages
English (en)
Spanish (es)
Inventor
Frederick Moss Stephen
Cui Haifeng
Hennessy Alan
Jin Qi
James Miles Timothy
David Pearson Neil
Original Assignee
Glaxosmithkline Ip Dev Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glaxosmithkline Ip Dev Ltd filed Critical Glaxosmithkline Ip Dev Ltd
Publication of MX2018002033A publication Critical patent/MX2018002033A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5383—1,4-Oxazines, e.g. morpholine ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/542—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/0075—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a dry powder inhaler [DPI], e.g. comprising micronized drug mixed with lactose carrier particles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C07D513/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Dispersion Chemistry (AREA)
  • Otolaryngology (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Medicinal Preparation (AREA)
MX2018002033A 2015-08-16 2016-08-15 Agentes antibacterianos que comprenden una pirazino[2,3-b] [1,4]oxazin-3-ona o un sistema de anillo relacionado. MX2018002033A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201562205732P 2015-08-16 2015-08-16
US201662308928P 2016-03-16 2016-03-16
PCT/IB2016/054890 WO2017029602A2 (en) 2015-08-16 2016-08-15 Compounds for use in antibacterial applications

Publications (1)

Publication Number Publication Date
MX2018002033A true MX2018002033A (es) 2018-06-15

Family

ID=57218948

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2018002033A MX2018002033A (es) 2015-08-16 2016-08-15 Agentes antibacterianos que comprenden una pirazino[2,3-b] [1,4]oxazin-3-ona o un sistema de anillo relacionado.

Country Status (22)

Country Link
US (2) US10364254B2 (enExample)
EP (1) EP3334739A2 (enExample)
JP (1) JP6757402B2 (enExample)
KR (1) KR20180038046A (enExample)
CN (1) CN108137616B (enExample)
AU (2) AU2016307969C1 (enExample)
CA (1) CA2995715A1 (enExample)
CL (1) CL2018000403A1 (enExample)
CO (1) CO2018002204A2 (enExample)
CR (1) CR20180111A (enExample)
DO (1) DOP2018000049A (enExample)
EA (1) EA033314B1 (enExample)
HK (1) HK1248680A1 (enExample)
IL (1) IL257265B (enExample)
MA (1) MA42621A (enExample)
MX (1) MX2018002033A (enExample)
PE (1) PE20181143A1 (enExample)
PH (1) PH12018500358A1 (enExample)
TW (1) TW201722965A (enExample)
UY (1) UY36851A (enExample)
WO (1) WO2017029602A2 (enExample)
ZA (1) ZA201800722B (enExample)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UY36851A (es) * 2015-08-16 2017-03-31 Glaxosmithkline Ip Dev Ltd Compuestos para uso en aplicaciones antibacterianas
WO2019180634A1 (en) 2018-03-23 2019-09-26 Glaxosmithkline Intellectual Property Development Limited Synthesis of oxazinone-containing bicyclic aromatic and heteroaromatic aldehydes
TW202116782A (zh) 2019-07-16 2021-05-01 瑞士商愛杜西亞製藥有限公司 喹啉酮衍生物
CN111269247B (zh) * 2020-03-04 2020-11-24 河南科技大学第一附属医院 具有抑制大肠杆菌作用的噻嗪酮药物分子的制备方法
KR20240161147A (ko) 2022-03-14 2024-11-12 슬랩 파마슈티컬스 엘엘씨 다중 사이클릭 화합물
AR134764A1 (es) 2023-12-21 2026-04-01 Glaxosmithkline Intellectual Property No 4 Ltd Compuestos químicos y usos de los mismos

Family Cites Families (88)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS4632671B1 (enExample) * 1969-10-13 1971-09-23 Eisai Co Ltd
US4235871A (en) 1978-02-24 1980-11-25 Papahadjopoulos Demetrios P Method of encapsulating biologically active materials in lipid vesicles
CY1308A (en) 1979-12-06 1985-12-06 Glaxo Group Ltd Device for dispensing medicaments
ATE23272T1 (de) 1981-07-08 1986-11-15 Draco Ab Pulverinhalator.
US4778054A (en) 1982-10-08 1988-10-18 Glaxo Group Limited Pack for administering medicaments to patients
GB2169265B (en) 1982-10-08 1987-08-12 Glaxo Group Ltd Pack for medicament
NL192564C (nl) 1982-10-08 1997-10-03 Glaxo Group Ltd Inrichting voor het toedienen van medicamenten aan patiënten.
EP0211595B1 (en) 1985-07-30 1991-11-13 Glaxo Group Limited Devices for administering medicaments to patients
JPH0733379B2 (ja) * 1986-06-27 1995-04-12 エーザイ株式会社 光学活性α−トコフエロ−ルの製造方法
HU213221B (en) 1990-03-02 1997-03-28 Glaxo Group Ltd Inhalation device and medicine packet for device
GB9004781D0 (en) 1990-03-02 1990-04-25 Glaxo Group Ltd Device
US6536427B2 (en) 1990-03-02 2003-03-25 Glaxo Group Limited Inhalation device
IL115849A0 (en) 1994-11-03 1996-01-31 Merz & Co Gmbh & Co Tangential filtration preparation of liposomal drugs and liposome product thereof
GB9700226D0 (en) 1997-01-08 1997-02-26 Glaxo Group Ltd Inhalation device
US5827533A (en) 1997-02-06 1998-10-27 Duke University Liposomes containing active agents aggregated with lipid surfactants
FR2798656B1 (fr) 1999-09-17 2004-12-17 Aventis Pharma Sa Derives de la quinolyl propyl piperidine, leur preparation et les compositions qui les contiennent
PL364808A1 (en) 2000-07-21 2004-12-13 Ljudmila Petrovna Maljuk Plate for a stand-up meal
NZ523749A (en) 2000-07-26 2005-03-24 Smithkline Beecham P Aminopiperidine quinolines and their azaisosteric analogues with antibacterial activity
FR2816618B1 (fr) 2000-11-15 2002-12-27 Aventis Pharma Sa Derives heterocyclylalcoyl piperidine, leur preparation et les compositions qui les contiennent
GB0031088D0 (en) 2000-12-20 2001-01-31 Smithkline Beecham Plc Medicaments
EP1345903A1 (en) 2000-12-21 2003-09-24 Ciba SC Holding AG Crystalline forms of cerivastatin sodium
GB0101577D0 (en) 2001-01-22 2001-03-07 Smithkline Beecham Plc Compounds
GB0112834D0 (en) * 2001-05-25 2001-07-18 Smithkline Beecham Plc Medicaments
GB0112836D0 (en) 2001-05-25 2001-07-18 Smithkline Beecham Plc Medicaments
GB0118238D0 (en) 2001-07-26 2001-09-19 Smithkline Beecham Plc Medicaments
GB0201677D0 (en) 2002-01-25 2002-03-13 Glaxo Group Ltd Medicament dispenser
WO2003064431A2 (en) 2002-01-29 2003-08-07 Glaxo Group Limited Aminopiperidine compounds, process for their preparation, and pharmaceutical compositions containing them
US7312212B2 (en) 2002-01-29 2007-12-25 Glaxo Group Limited Aminopiperidine derivatives
US20060014786A1 (en) * 2002-05-17 2006-01-19 Rajeev Raut Opthalmic pharmaceutical compositions and methods for treating ocular inflammation
TW200406413A (en) 2002-06-26 2004-05-01 Glaxo Group Ltd Compounds
TW200409637A (en) * 2002-06-26 2004-06-16 Glaxo Group Ltd Compounds
CN100427487C (zh) 2002-06-27 2008-10-22 弗·哈夫曼·拉罗切有限公司 嘌呤衍生物的合成
GB0217294D0 (en) 2002-07-25 2002-09-04 Glaxo Group Ltd Medicaments
FR2844268B1 (fr) 2002-09-11 2004-10-22 Aventis Pharma Sa Derives de la quinolyl propyl piperidine, leurs procedes et intermediaires de preparation et les compositions qui les contiennent
FR2844270B1 (fr) 2002-09-11 2006-05-19 Aventis Pharma Sa Derives de la quinolyl propyl piperidine, leur procede et intermediaires de preparation et les compositions qui les contiennent
EP1551829B1 (de) 2002-10-10 2010-04-07 Morphochem Aktiengesellschaft Für Kombinatorische Chemie Neue verbindungen mit antibakterieller aktivität
AU2003291227A1 (en) 2002-11-05 2004-06-07 Smithkline Beecham Corporation Antibacterial agents
ES2340484T3 (es) 2002-11-05 2010-06-04 Glaxo Group Limited Agentes antibacterianos.
AR042486A1 (es) 2002-12-18 2005-06-22 Glaxo Group Ltd Compuesto de quinolina y naftiridina halosustituido en la posicion 3, procedimiento para preparar el compuesto, composicion farmaceutica que lo comprende y su uso para preparar dicha composicion .
TW200507841A (en) * 2003-03-27 2005-03-01 Glaxo Group Ltd Antibacterial agents
FR2852954B1 (fr) 2003-03-28 2006-07-14 Aventis Pharma Sa Derives de quinoleines-4-substituees, leurs procede et intermediaires de preparation et les compositions pharmaceutiques qui les contiennent
DE10316081A1 (de) 2003-04-08 2004-10-21 Morphochem AG Aktiengesellschaft für kombinatorische Chemie Neue Verbindungen mit antibakterieller Aktivität
FR2858619B1 (fr) 2003-08-08 2006-12-22 Aventis Pharma Sa Derives de quinoleines-4-substituees, leurs procede et intermediaires de preparation et les compositions pharmaceutiques qui les contiennent
US9214590B2 (en) 2003-12-19 2015-12-15 The University Of North Carolina At Chapel Hill High fidelity nano-structures and arrays for photovoltaics and methods of making the same
US8263129B2 (en) 2003-12-19 2012-09-11 The University Of North Carolina At Chapel Hill Methods for fabricating isolated micro-and nano-structures using soft or imprint lithography
FR2867472B1 (fr) 2004-03-12 2008-07-18 Aventis Pharma Sa Derives de quinoleines-4-substituees, leurs procede et intermediaires de preparation et les compositions pharmaceutiques qui les contiennent
JP2008502689A (ja) 2004-06-15 2008-01-31 グラクソ　グループ　リミテッド 抗菌剤
FR2872164B1 (fr) 2004-06-29 2006-11-17 Aventis Pharma Sa Derives de quinoleines-4-substituees, leur procede et intermediaires de preparation et les compositions pharmaceutiques qui les contiennent
EP1773831A1 (en) 2004-07-08 2007-04-18 Glaxo Group Limited Antibacterial agents
EP1773847A2 (en) * 2004-07-09 2007-04-18 Glaxo Group Limited Antibacterial agents
JP2008506695A (ja) 2004-07-13 2008-03-06 グラクソ　グループ　リミテッド 抗細菌剤
JP2008507543A (ja) 2004-07-22 2008-03-13 グラクソ　グループ　リミテッド 抗細菌剤
JP2008508359A (ja) 2004-08-02 2008-03-21 グラクソ グループ リミテッド 抗菌剤
JP2008509222A (ja) 2004-08-09 2008-03-27 グラクソ グループ リミテッド 抗菌剤
DE102004041163A1 (de) * 2004-08-25 2006-03-02 Morphochem Aktiengesellschaft für kombinatorische Chemie Neue Verbindungen mit antibakterieller Aktivität
JP4887297B2 (ja) 2004-09-24 2012-02-29 アクテリオン ファーマシューティカルズ リミテッド 新規二環式抗生物質
DE602005021133D1 (de) 2004-10-05 2010-06-17 Actelion Pharmaceuticals Ltd Neue piperidin-antibiotika
WO2006046552A1 (ja) 2004-10-27 2006-05-04 Toyama Chemical Co., Ltd. 新規な含窒素複素環化合物およびその塩
WO2006081264A1 (en) * 2005-01-25 2006-08-03 Glaxo Group Limited Antibacterial agents
WO2006125974A1 (en) * 2005-05-24 2006-11-30 Astrazeneca Ab Aminopiperidine quinolines and their azaisosteric analogues with antibacterial activity
MY150958A (en) 2005-06-16 2014-03-31 Astrazeneca Ab Compounds for the treatment of multi-drug resistant bacterial infections
WO2006137485A1 (ja) 2005-06-24 2006-12-28 Toyama Chemical Co., Ltd. 新規な含窒素複素環化合物およびその塩
GB0515584D0 (en) 2005-07-28 2005-09-07 Glaxo Group Ltd Medicament dispenser
EP1922364A4 (en) 2005-08-09 2010-04-21 Univ North Carolina METHOD AND MATERIALS FOR PRODUCING MICROFLUIDIC DEVICES
AR058289A1 (es) 2005-12-12 2008-01-30 Glaxo Group Ltd Colector para ser usado en dispensador de medicamento
DOP2006000268A (es) 2005-12-22 2007-07-31 Pfizer Prod Inc Agentes antibacterianos
WO2007081876A2 (en) 2006-01-04 2007-07-19 Liquidia Technologies, Inc. Nanostructured surfaces for biomedical/biomaterial applications and processes thereof
WO2007093963A1 (en) * 2006-02-15 2007-08-23 Actelion Pharmaceuticals Ltd Ethanol or 1,2-ethanediol cyclohexyl antibiotic derivatives
MX2008014908A (es) 2006-05-26 2009-05-13 Toyama Chemical Co Ltd Compuesto heterociclico nuevo o sal del mismo e intermedio del mismo.
EP1992628A1 (en) * 2007-05-18 2008-11-19 Glaxo Group Limited Derivatives and analogs of N-ethylquinolones and N-ethylazaquinolones
US8465775B2 (en) 2006-07-27 2013-06-18 The University Of North Carolina At Chapel Hill Nanoparticle fabrication methods, systems, and materials for fabricating artificial red blood cells
US8128393B2 (en) 2006-12-04 2012-03-06 Liquidia Technologies, Inc. Methods and materials for fabricating laminate nanomolds and nanoparticles therefrom
CL2007003693A1 (es) * 2006-12-22 2008-06-27 Actelion Pharmaceuticals Ltd Compuestos derivados de pirido [3,2-b] [1,4] tiazina; composicion farmaceutica que contiene dichos compuestos; y su uso en el tratamiento de infecciones bacterianas.
GB0707704D0 (en) * 2007-04-20 2007-05-30 Glaxo Group Ltd Compounds
WO2009024342A2 (en) * 2007-08-23 2009-02-26 Syngenta Participations Ag Novel microbiocides
CN101896337B (zh) 2007-10-12 2013-10-30 流体科技公司 用于生产颗粒和图案化膜的系统和方法
JP5620636B2 (ja) 2007-11-26 2014-11-05 富山化学工業株式会社 新規な複素環化合物またはその塩を含有する抗菌剤
KR101294962B1 (ko) * 2008-10-07 2013-08-12 액테리온 파마슈티칼 리미티드 트리사이클 옥사졸리디논 항생제 화합물
WO2010045987A1 (en) * 2008-10-23 2010-04-29 Glaxo Group Limited Substituted (aza) -1-methyl-1h-quin0lin-2-0nes as antibacterials
TW201022279A (en) * 2008-11-14 2010-06-16 Astrazeneca Ab Chemical compounds
KR101880582B1 (ko) 2008-12-05 2018-07-20 리퀴디아 테크놀로지스 인코포레이티드 패턴 재료 제조 방법
CN102232078B (zh) * 2008-12-12 2014-07-16 埃科特莱茵药品有限公司 5-氨基-2-(1-羟基-乙基)-四氢吡喃衍生物
WO2011008737A2 (en) 2009-07-13 2011-01-20 The University Of North Carolina At Chapel Hill Engineered aerosol particles, and associated methods
TW201209056A (en) * 2010-05-25 2012-03-01 Taisho Pharmaceutical Co Ltd Novel heterocyclic compound or salt thereof
AU2012275499A1 (en) * 2011-06-27 2013-12-19 Kyorin Pharmaceutical Co., Ltd. Bridged bicyclic compounds for the treatment of bacterial infections
EP2785721A1 (en) * 2011-11-30 2014-10-08 Actelion Pharmaceuticals Ltd. 3,7-disubstituted octahydro-2h-pyrido[4,3-e][1,3]oxazin-2-one antibiotics
EA029361B1 (ru) 2013-04-16 2018-03-30 Идорсиа Фармасьютиклз Лтд Антибактериальные биароматические производные
UY36851A (es) * 2015-08-16 2017-03-31 Glaxosmithkline Ip Dev Ltd Compuestos para uso en aplicaciones antibacterianas

Also Published As

Publication number Publication date
AU2019200226B2 (en) 2020-01-23
JP6757402B2 (ja) 2020-09-16
DOP2018000049A (es) 2018-03-30
US20190270755A1 (en) 2019-09-05
UY36851A (es) 2017-03-31
ZA201800722B (en) 2019-07-31
CN108137616B (zh) 2020-06-26
US10683307B2 (en) 2020-06-16
MA42621A (fr) 2018-06-20
PH12018500358A1 (en) 2018-09-03
JP2018523675A (ja) 2018-08-23
CN108137616A (zh) 2018-06-08
AU2019200226A1 (en) 2019-01-31
EA201890412A1 (ru) 2018-08-31
KR20180038046A (ko) 2018-04-13
TW201722965A (zh) 2017-07-01
US20190031680A1 (en) 2019-01-31
CA2995715A1 (en) 2017-02-23
IL257265A (en) 2018-03-29
CO2018002204A2 (es) 2018-06-20
CL2018000403A1 (es) 2018-07-06
AU2016307969A1 (en) 2018-03-08
HK1248680A1 (zh) 2018-10-19
AU2016307969C1 (en) 2019-09-05
EP3334739A2 (en) 2018-06-20
CR20180111A (es) 2018-04-12
PE20181143A1 (es) 2018-07-17
US10364254B2 (en) 2019-07-30
EA033314B1 (ru) 2019-09-30
WO2017029602A2 (en) 2017-02-23
WO2017029602A3 (en) 2017-04-13
AU2016307969B2 (en) 2019-02-14
IL257265B (en) 2020-07-30

Similar Documents

Publication Publication Date Title
AU2019264537A1 (en) Beta-lactamase inhibitors
MX2016016593A (es) Nuevos derivados de aminoalquibenzotiazepina y usos de los mismos.
PH12016501577A1 (en) Monobactam organic compounds for the treatment of bacterial infections
PH12014501991B1 (en) Phenicol antibacterials
HK1248680A1 (zh) 包含吡嗪并[2，3-b][1，4]恶嗪-3-酮或相关环系的抗菌剂
MX2016009251A (es) Derivados de 7-oxo-1, 6-diazabiciclo [3.2.1] octano y su uso como agentes antibacterianos.
TW201613864A (en) Novel compounds
PH12019502509A1 (en) Compounds and methods for treating bacterial infections
WO2016100578A3 (en) Antimicrobial polymyxins for treatment of bacterial infections
MX2019011908A (es) Macrociclos de peptidos anti-bacterianos y uso de los mismos.
MX2019006768A (es) Peptidos antimicrobianos.
PH12016501532A1 (en) Antibacterial combinations comprising polymyxin
AU2015280874A1 (en) Novel heterocyclic compound
MX2018011095A (es) Compuestos de carbapenem.
MX2015015251A (es) Derivados de la quinolona.
NZ737820A (en) Mannose derivatives for treating bacterial infections
PH12015500518A1 (en) Tricyclic tetrahydroquinoline antibacterial agents
MX2015014657A (es) Nuevos agentes antibacterianos de fenicol.
MY186775A (en) Antibacterial compositions and methods
WO2014147578A3 (en) Antibacterial compounds against drug resistant bacteria
MX2014004742A (es) Nuevos agentes antibacterianos de fenicol.
HK1241754A1 (en) Pulmonary administration of pyocins for treating bacterial respiratory infections
ZA201705781B (en) Pharmaceutical compositions for the treatment of bacterial infections
JO3477B1 (ar) مركبات أحادي باكتام عضوية لعلاج العدوى البكتيرية
HK1228395A1 (en) Antibacterial compounds